Renin–angiotensin system blockade after transcatheter aortic valve replacement (TAVR) improves intermediate survival

Introduction: Hypertension is common in patients with severe aortic stenosis undertaking transcatheter aortic valve replacement (TAVR). Renin–angiotensin system (RAS) blockade therapy with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) has recently been a...

Descripción completa

Detalles Bibliográficos
Autor principal: Klinkhammer, Brent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759619/
https://www.ncbi.nlm.nih.gov/pubmed/31579456
http://dx.doi.org/10.15171/jcvtr.2019.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759619/
https://www.ncbi.nlm.nih.gov/pubmed/31579456
http://dx.doi.org/10.15171/jcvtr.2019.30

Ejemplares similares